{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:44:43Z","timestamp":1781232283013,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Statin intake is associated with muscular side effects, among which the unmasking of latent myopathies and of malignant hyperthermia (MH) susceptibility have been reported. These findings, together with experimental data in small animals, prompt speculation that statin therapy may compromise the performance of skeletal muscle during diagnostic in vitro contracture tests (IVCT). In addition, statins might reduce triggering thresholds in susceptible individuals (MHS), or exacerbate MH progression. We sought to obtain empirical data to address these questions.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We compared the responses of 3 different muscles from untreated or simvastatin treated MHS and non-susceptible (MHN) pigs. MHS animals were also invasively monitored for signs of impending MH during sevoflurane anesthesia.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Muscles from statin treated MHS pigs responded with enhanced in vitro contractures to halothane, while responses to caffeine were unaltered by the treatment. Neither agent elicited contractures in muscles from statin treated MHN pigs. In vivo, end- tide pCO2, hemodynamic evolution, plasma pH, potassium and lactate concentrations consistently pointed to mild acceleration of MH development in statin-treated pigs, whereas masseter spasm and rigor faded compared to untreated MHS animals.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The diagnostic sensitivity and specificity of the IVCT remains unchanged by a short-term simvastatin treatment in MHS swine. Evidence of modest enhancement in cardiovascular and metabolic signs of MH, as well as masked pathognomonic muscle rigor observed under simvastatin therapy suggest a potentially misleading influence on the clinical presentation of MH. The findings deserve further study to include other statins and therapeutic regimes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12871-020-01186-5","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T10:02:54Z","timestamp":1603447374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of statin intake on malignant hyperthermia: an in vitro and in vivo swine study"],"prefix":"10.1186","volume":"20","author":[{"given":"Asensio","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinen L.","family":"Iles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Iaizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2217-1068","authenticated-orcid":false,"given":"Oliver","family":"Bandschapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"1186_CR1","doi-asserted-by":"crossref","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet. 1994;344:1383\u20139.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"1186_CR2","doi-asserted-by":"crossref","unstructured":"Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, L\u00f3pez-Jaramillo P, Leiter LA, Dans A, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021\u201331.","DOI":"10.1056\/NEJMoa1600176"},{"key":"1186_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/MOL.0000000000000174","volume":"26","author":"BA Taylor","year":"2015","unstructured":"Taylor BA, Thompson PD. Muscle-related side-effects of statins: from mechanisms to evidence-based solutions. Curr Opin Lipidol. 2015;26:221\u20137.","journal-title":"Curr Opin Lipidol"},{"key":"1186_CR4","doi-asserted-by":"crossref","unstructured":"Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pearson GJ, et al. Diagnosis, prevention, and Management of Statin Adverse Effects and Intolerance: Canadian consensus working group update (2016). Can J Cardiol. 2016;32:S35\u201365.","DOI":"10.1016\/j.cjca.2016.01.003"},{"key":"1186_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1365-2796.2005.01515.x","volume":"258","author":"NC Voermans","year":"2005","unstructured":"Voermans NC, Lammens M, Wevers RA, Hermus AR, van Engelen BG. Statin-disclosed acid maltase deficiency. J Intern Med. 2005;258:196\u20137.","journal-title":"J Intern Med"},{"key":"1186_CR6","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/archinte.166.14.1519","volume":"166","author":"G Tsivgoulis","year":"2006","unstructured":"Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med. 2006;166:1519\u201324.","journal-title":"Arch Intern Med"},{"key":"1186_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00296-017-3821-3","volume":"38","author":"IBP Borges","year":"2018","unstructured":"Borges IBP, Silva MG, Misse RG, Shinjo SK. Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review. Rheumatol Int. 2018;38:293\u2013301.","journal-title":"Rheumatol Int"},{"key":"1186_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMra1515161","volume":"374","author":"AL Mammen","year":"2016","unstructured":"Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374:664\u20139.","journal-title":"N Engl J Med"},{"key":"1186_CR9","doi-asserted-by":"crossref","unstructured":"Ramos-Fransi A, Mart\u00ednez-Pi\u00f1eiro A, Almendrote M, Lucente G, Carrato C, Ballester-Lopez A, Lucia A, Pintos-Morell G, Nogales-Gadea G, Coll-Cant\u00ed J. Myotilinopathy unmasked by statin treatment: a case report. Muscle Nerve. 2018;57:E138\u2013E40.","DOI":"10.1002\/mus.26078"},{"key":"1186_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1056\/NEJMc081975","volume":"360","author":"GD Vladutiu","year":"2009","unstructured":"Vladutiu GD, Isackson PJ. SLCO1B1 variants and statin-induced myopathy. N Engl J Med. 2009;360:304.","journal-title":"N Engl J Med"},{"key":"1186_CR11","doi-asserted-by":"crossref","unstructured":"Venturi E, Lindsay C, Lotteau S, Yang Z, Steer E, Witschas K, Wilson AD, Wickens JR, Russell AJ, Steele D, et al. Simvastatin activates single skeletal RyR1 channels but exerts more complex regulation of the cardiac RyR2 isoform. Br J Pharmacol. 2018;175:938\u201352.","DOI":"10.1111\/bph.14136"},{"key":"1186_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1755-5922.2010.00237.x","volume":"28","author":"T Metterlein","year":"2010","unstructured":"Metterlein T, Schuster F, Tadda L, Hager M, Roewer N, Anetseder M. Statins alter intracellular calcium homeostasis in malignant hyperthermia susceptible individuals. Cardiovasc Ther. 2010;28:356\u201360.","journal-title":"Cardiovasc Ther"},{"key":"1186_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2044-5040-3-22","volume":"3","author":"M Knoblauch","year":"2013","unstructured":"Knoblauch M, Dagnino-Acosta A, Hamilton SL. Mice with RyR1 mutation (Y524S) undergo hypermetabolic response to simvastatin. Skelet Muscle. 2013;3:22.","journal-title":"Skelet Muscle"},{"key":"1186_CR14","doi-asserted-by":"crossref","unstructured":"Guis S, Figarella-Branger D, Mattei JP, Nicoli F, Le Fur Y, Kozak-Ribbens G, Pellissier JF, Cozzone PJ, Amabile N, Bendahan D. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum. 2006;55:551\u20137.","DOI":"10.1002\/art.22100"},{"key":"1186_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/00003643-200407000-00013","volume":"21","author":"R Krivosic-Horber","year":"2004","unstructured":"Krivosic-Horber R, D\u00e9pret T, Wagner JM, Maurage CA. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol. 2004;21:572\u20134.","journal-title":"Eur J Anaesthesiol"},{"key":"1186_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00228-014-1776-9","volume":"71","author":"K Hedenmalm","year":"2015","unstructured":"Hedenmalm K, Granberg AG, Dahl ML. Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives. Eur J Clin Pharmacol. 2015;71:117\u201324.","journal-title":"Eur J Clin Pharmacol"},{"key":"1186_CR17","doi-asserted-by":"crossref","unstructured":"Hopkins PM, R\u00fcffert H, Snoeck MM, Girard T, Glahn KP, Ellis FR, M\u00fcller CR, Urwyler A. European malignant hyperthermia group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth. 2015;115:531\u20139.","DOI":"10.1093\/bja\/aev225"},{"key":"1186_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1213\/00000539-199407000-00027","volume":"79","author":"PA Iaizzo","year":"1994","unstructured":"Iaizzo PA, Wedel DJ. Response to succinylcholine in porcine malignant hyperthermia. Anesth Analg. 1994;79:143\u201351.","journal-title":"Anesth Analg"},{"key":"1186_CR19","volume-title":"Malignant hyperthermia","author":"GG Harrison","year":"1987","unstructured":"Harrison GG. Porcine malignant hyperthermia-the Saga of the \u201chot\u201d pig. In: Britt BA, editor. Malignant hyperthermia. Boston: Springer; 1987."},{"key":"1186_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/bja\/aer132","volume":"107","author":"PM Hopkins","year":"2011","unstructured":"Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth. 2011;107:48\u201356.","journal-title":"Br J Anaesth"},{"key":"1186_CR21","doi-asserted-by":"crossref","unstructured":"Busnelli M, Froio A, Bacci ML, Giunti M, Cerrito MG, Giovannoni R, Forni M, Gentilini F, Scagliarini A, Deleo G, et al. Pathogenetic role of hypercholesterolemia in a novel preclinical model of vascular injury in pigs. Atherosclerosis. 2009;207:384\u201390.","DOI":"10.1016\/j.atherosclerosis.2009.05.022"},{"key":"1186_CR22","doi-asserted-by":"crossref","unstructured":"Weinrich M, Nanda H, Worcester DL, Majkrzak CF, Maranville BB, Bezrukov SM. Halothane changes the domain structure of a binary lipid membrane. Langmuir. 2012;28:4723\u20138.","DOI":"10.1021\/la204317k"},{"key":"1186_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bja.2018.08.009","volume":"122","author":"L Figueroa","year":"2019","unstructured":"Figueroa L, Kraeva N, Manno C, Toro S, Rios E, Riazi S. Abnormal calcium signalling and the caffeine-halothane contracture test. Br J Anaesth. 2019;122:32\u201341.","journal-title":"Br J Anaesth"},{"key":"1186_CR24","doi-asserted-by":"crossref","unstructured":"Singal A, Mattison LM, Soule CL, Ballard JR, Rudie EN, Cressman ENK, Iaizzo PA. Assessment of ablative therapies in swine: response of respiratory diaphragm to varying doses. Ann Biomed Eng. 2018;46(7):947\u201359.","DOI":"10.1007\/s10439-018-2014-x"},{"key":"1186_CR25","doi-asserted-by":"crossref","unstructured":"Osaki Y, Nakagawa Y, Miyahara S, Iwasaki H, Ishii A, Matsuzaka T, Kobayashi K, Yatoh S, Takahashi A, Yahagi N, et al. Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: a model for statin-induced myopathy. Biochem Biophys Res Commun. 2015;466:536\u201340.","DOI":"10.1016\/j.bbrc.2015.09.065"},{"key":"1186_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.toxlet.2019.03.001","volume":"307","author":"K Watanabe","year":"2019","unstructured":"Watanabe K, Oda S, Matsubara A, Akai S, Yokoi T. Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate. Toxicol Lett. 2019;307:49\u201358.","journal-title":"Toxicol Lett"},{"key":"1186_CR27","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/eci.12461","volume":"45","author":"M Apostolopoulou","year":"2015","unstructured":"Apostolopoulou M, Corsini A, Roden M. The role of mitochondria in statin-induced myopathy. Eur J Clin Investig. 2015;45:745\u201354.","journal-title":"Eur J Clin Investig"},{"key":"1186_CR28","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1124\/jpet.106.118331","volume":"321","author":"A Liantonio","year":"2007","unstructured":"Liantonio A, Giannuzzi V, Cippone V, Camerino GM, Pierno S, Camerino DC. Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum\/mitochondria Ca2+\u2212release system. J Pharmacol Exp Ther. 2007;321:626\u201334.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-020-01186-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-020-01186-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-020-01186-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T19:22:58Z","timestamp":1634930578000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-020-01186-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1186"],"URL":"https:\/\/doi.org\/10.1186\/s12871-020-01186-5","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"assertion":[{"value":"9 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study and the experimental protocol were approved and conducted in accordance to the Institutional Animal Care and Use Committee of the University of Minnesota (IACUC; ID 1308-30893A, Minneapolis, USA).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"270"}}